Á¦ 73Â÷ ´ëÇѺñ´¢ÀÇÇÐȸ Á¤±âÇмú´ëȸ (DAY3) : 2021-11-05±³À°ÀÏÀÚ : 2021-11-05
±³À°Àå¼Ò : ¼¿ï COEX Grand Ballroom A(Room101+102+103)
±³À°ÁÖÁ¦ :
Á¦ 73Â÷ ´ëÇѺñ´¢ÀÇÇÐȸ Á¤±âÇмú´ëȸ (DAY3)ÁÖÃÖ±â°ü : ´ëÇѺñ´¢ÀÇÇÐȸ(19.2 ¸íĪº¯°æ ´ëÇѺñ´¢±â°úÇÐȸ)
´ã´çÀÚ : ±èÁöÇü
¿¬¶ôó : 02-573-8190
À̸ÞÀÏ :
urology@urology.or.kr ±³À°Á¾·ù : ºñ´¢ÀÇÇаú
Âü¼®¿¹»óÀοø : 900¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 6 ½Ã°£ 0ºÐ
¼¼ºÎ¼ö°·á : 110,000¿ø
ºñ°í ºÀÁ÷ȸ¿ø: 110,000¿ø/°³¿øȸ¿ø: 110,000¿ø/±ºÀÇ°ü,°øº¸ÀÇ: 66,000¿ø/Àü°øÀÇ: 66,000¿ø/Ÿ°úÀü¹®ÀÇ:120,000¿ø/Ÿ°úÀü¹®ÀÇ(1Àϵî·Ï):88,000¿ø/°£È£»ç: 66,000¿ø/°£È£»ç(1Àϵî·Ï):33,000¿ø/¿¬±¸¿ø:66,000¿ø/Á¦¾àȸ»ç ¹× ÀÇ·á±âȸ»ç: 120,000¿ø *»çÀüµî·Ï ±âÁØ
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 11-05 Grand Ballroom A(Room101+102+103) 09:00~09:15 Daily highlight ±è¼ºÇÑ(±¹¸³¾Ï¼¾Å¸)
±³À°½Ã°£ 11-05 Grand Ballroom A(Room101+102+103) 09:15~09:30 Active surveillance in low risk bladder cancer Á¤½ÂÀÏ(Àü³²ÀÇ´ë)
±³À°½Ã°£ 11-05 Grand Ballroom A(Room101+102+103) 09:30~09:45 Molecular biomarkers for response of neoadjuvant chemotherapy in MIBC ÀåÀÎÈ£(Áß¾ÓÀÇ´ë)
±³À°½Ã°£ 11-05 Grand Ballroom A(Room101+102+103) 09:45~10:00 Evoling landscape of management for metastatic hormone-sensitive prostate cancer (mHSPC) Á¤À翵(±¹¸³¾Ï¼¾ÅÍ)
±³À°½Ã°£ 11-05 Grand Ballroom A(Room101+102+103) 10:00~10:15 Radiomics as a novel approach to improved characterization of small renal masses È«¼ºÈÄ(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 11-05 Grand Ballroom A(Room101+102+103) 10:15~10:30 Comparative estimating the impact of PSA screening in Asia America-Europe °í¿µÈÖ(¿µ³²ÀÇ´ë)
±³À°½Ã°£ 11-05 Grand Ballroom A(Room101+102+103) 10:30~10:45 Future perspectives of microbiomics and urolithiasis ÀÌÁÖ¿ë(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 11-05 Grand Ballroom A(Room101+102+103) 10:45~11:00 The effectiveness of percutaneous tibial nerve stimulation for overactive bladder syndrome Ã߹μö(¼¿ïÀÇ´ë)
±³À°½Ã°£ 11-05 Grand Ballroom A(Room101+102+103) 11:00~11:15 Treatment strategy for bladder outlet obstruction in middle age ½Åµ¿±æ(ºÎ»êÀÇ´ë)
±³À°½Ã°£ 11-05 Grand Ballroom A(Room101+102+103) 11:15~11:30 Anticholinergic burden in Adults with overactive bladder: Focus on multiple anticholinergic use Á¶¿µ»ï(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 11-05 Grand Ballroom A(Room101+102+103) 11:30~11:45 Impact of male circumcision on sexual function ÀÌ¿ø±â(ÇѸ²ÀÇ´ë)
±³À°½Ã°£ 11-05 Grand Ballroom A(Room101+102+103) 11:45~12:00 UTI vaccine as an alternative to antibiotics Á¤È«(°Ç±¹ÀÇ´ë)
½Ä»ç 11-05 12:00~13:00 ½Ä»ç ()
±³À°½Ã°£ 11-05 D (Room.203) 13:00~13:05 Apalutamide for Metastatic Castration-Sensitive Prostate Cancer: Outcomes in High-Volume and Low-Volume Disease From the TITAN Final Analysis Á¤º´ÇÏ(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 11-05 D (Room.203) 13:05~13:10 Prognostic impact of sarcopenia in patients with metastatic hormone-sensitive prostate cancer treated by either early docetaxel or abiraterone acetate ±èÁرÔ(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 11-05 D (Room.203) 13:10~13:15 Outcomes of metastatic lymph node only hormone naive and castrate resistant prostate cancer treated with PSMA-Lutetium radioligand therapy William Yaxley(QEII Jubilee Hospital Brisbane Australia)
±³À°½Ã°£ 11-05 D (Room.203) 13:15~13:20 Initial experience of [177Lu]Ludotadipep treatment in patients with [18F]PSMA PET CT positive metastatic castration-resistant prostate cancer ½Åµ¿È£(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 11-05 D (Room.203) 13:20~13:25 The value of [F-18]Florastamin Prostate Specific membranous antigen (PSMA) PET/CT at initial diagnosis of prostate cancer compared with multi-parametric magnetic resonance imaging (mpMRI) ±ÇÇõÀç(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 11-05 D (Room.203) 13:25~13:30 Prediction of clinically significant prostate cancer using polygenic risk models in Asians ¼Û»óÇå(¼¿ïÀÇ´ë)
±³À°½Ã°£ 11-05 D (Room.203) 13:30~13:35 Relapse Rates after LDR Brachytherapy for low and intermediate risk Prostate Cancer: 6-year median follow up at a tertiary referral centre Athos Katelaris(Department of Urology St George Hospital Sydney Australia)
±³À°½Ã°£ 11-05 D (Room.203) 13:35~13:40 Effect of the ultrasound characteristics of regions of interest by MRI and additional target biopsy around the borderline on the detection of prostate cancer in MRI/TRUS software fusion biopsy ¼Û¿øÈÆ(ºÎ»êÀÇ´ë)
±³À°½Ã°£ 11-05 D (Room.203) 13:40~13:45 Usefulness of grayscale values of hypoechoic lesions matched with target lesions observed on magnetic resonance imaging for the prediction of clinically significant prostate cancer ±èµ¿±Õ(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 11-05 D (Room.203) 13:45~13:50 Reliability of a combination of targeted and systematic prostate biopsies in patients with MRI-visible lesions: A comparison study between combined biopsies and prostatectomy specimens ³ëÅÂÀÏ(°í·ÁÀÇ´ë)
±³À°½Ã°£ 11-05 D (Room.203) 13:50~13:55 Weekly versus 2-weekly versus 3-weekly docetaxel to treat metastatic castration-resistant prostate cancer °í¿ë¼®(¼¿ïÀÇ´ë)
±³À°½Ã°£ 11-05 D (Room.203) 13:55~14:00 Åä·Ð ()
±³À°½Ã°£ 11-05 D (Room.203) 14:00~15:00 Robotic ureteroplasty with buccal mucosa graft ÇÑ´öÇö(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 11-05 D (Room.203) 15:00~16:00 Excision and primary anastomosis for bulbar urethral stricture: Step-by-step technique ±è¼ö¿õ(¼¿ïÀÇ´ë)